WIRE — WASHINGTON — A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, AP reported. The Food and Drug Administration is evaluating Moderna's new shot, dubbed mFlusiva, for older Americans ahead of the The post FDA panel backs first-of-its-kind flu vaccine using mRNA technology appeared first on Egyptian Gazette.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.